Hologic acquires Gynesonics for US $350 million

USA – Hologic Inc., a leading breast imaging company, has completed its US $350 million acquisition of Gynesonics, a rival specializing in innovative ultrasound imaging technology.

The acquisition, finalized on January 6, adds the Sonata System to Hologic’s product portfolio, marking a significant step in the company’s efforts to enhance women’s health solutions.

Gynesonics, based in Redwood City, California, developed the Sonata System, a groundbreaking device that combines real-time ultrasound imaging with targeted radiofrequency ablation to diagnose and treat symptomatic fibroids without the need for incisions.

It is the first FDA-cleared product of its kind, offering an effective, minimally invasive solution for reducing fibroid-related symptoms.

Hologic, headquartered in Marlborough, Massachusetts, views the acquisition as a strategic complement to its existing offerings.

By integrating the Sonata System, the company aims to provide physicians with a broader range of options for managing heavy periods and fibroids, conditions that affect millions of women worldwide.

The acquisition was first announced in October 2024, a period marked by a resurgence in medtech mergers and acquisitions following a slowdown in 2023.

Commenting on the acquisition, Skip Baldino, President and CEO of Gynesonics, expressed optimism about the future of the Sonata System under Hologic’s leadership.

He emphasized the impact the technology has already had, stating, “We are excited to see the continued success of the Sonata System, which has already made a difference in the lives of thousands of women.“

This acquisition is the latest in a series of strategic purchases by Hologic since 2020, reflecting its focus on strengthening its portfolio through targeted acquisitions.

Previous purchases include Endomagnetics for US $310 million, Biotheranostics for US $230 million, Somatex for US $64 million, and Acessa Health for US $80 million.

Notably, Acessa Health produces the Acessa ProVu system, a direct competitor to the Sonata System.

Industry analysts at William Blair have noted that Hologic’s acquisition strategy often targets companies with products in the early stages of growth.

These acquisitions benefit from Hologic’s robust infrastructure, enabling the company to maximize the potential of these technologies while maintaining flexibility for further acquisitions or share buybacks.

The purchase of Gynesonics aligns with this strategy, offering promising growth prospects for the future. Hologic plans to release its latest quarterly earnings report on February 5.